Belite Bio, Inc
- BLTE
- NASDAQ
- Biotechnology
- Ophthalmology Biotech
- Retinal Disease (Stargardt/AMD)
$147.34
Today +3.19%Quote Oct 19, 2026, 08:00 PM UTC
−13.82%over the last month
Max drawdown −18.6%From 1-month high −16.0%3 months −8.5%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Belite Bio
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease.
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
41
Founded
2016
Market value
$5.93B
Quote Oct 19
Floor
$146.19
0.8% below price
Resistance
$148.47
0.8% above price
Price vs analyst targets
6 analysts
Lowest target
$206.00Highest target
$303.00
$206.00Highest target
$303.00
- Price $147.34
- Average target $245.83
- Analysts' target range
The price is below even the lowest analyst target. Analysts' average target sits about 67% higher.
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about BLTEPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free